文章：

一线塞普替尼与标准疗法在RET激活癌症患者中的比较效果：LIBRETTO-001研究的患者间探索性分析

Comparative Effectiveness of First-Line Selpercatinib versus Standard Therapies in Patients with RET-Activated Cancers: An Exploratory Interpatient Analysis of LIBRETTO-001

原文发布日期：27 December 2023

DOI: 10.3390/cancers16010140

类型: Article

开放获取: 是

英文摘要：

Selpercatinib is indicated for locally advanced/metastaticRET-activated solid tumors after progression or following prior systemic therapies. Until the recently published data from LIBRETTO-431 and LIBRETTO-531, there were limited effectiveness data comparing selpercatinib with other first-line treatments inRET-activated non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and thyroid cancer (TC). This study analyzed patient data from LIBRETTO-001 and compared the outcomes (time to treatment discontinuation {TTD}, time to next treatment or death {TTNT-D}, time to progression {TTP}, and the objective response rate {ORR}) of first-line selpercatinib (selpercatinib arm) use with the outcomes of first-line standard therapies in patients who then received selpercatinib in later lines of treatment (comparator arm). Overall, the first-line selpercatinib arm had a longer TTD, TTNT-D, and TTP versus the first-line comparator arm. The hazard ratios (HRs) for TTD were 0.29 (NSCLC), 0.15 (MTC), 0.08 (TC); for TTNT-D, the HRs were 0.48 (NSCLC), 0.11 (MTC), 0.09 (TC); and for TTP, the HRs were 0.54 (NSCLC), 0.15 (MTC), and 0.12 (TC). The ORR was higher for first-line selpercatinib versus the first-line comparator (NSCLC: 85.3% vs. 39.7%; MTC: 82.6% vs. 15.2%; and TC: 81.8% vs. 31.8%). First-line selpercatinib use is associated with improved outcomes compared to first-line comparator therapies for patients with advanced/metastaticRET-activated cancers.

摘要翻译： 

塞尔帕替尼适用于局部晚期/转移性RET激活实体瘤患者，在疾病进展或既往接受过全身治疗后使用。在LIBRETTO-431和LIBRETTO-531研究数据发布前，关于塞尔帕替尼与其它一线治疗方案在RET激活非小细胞肺癌（NSCLC）、甲状腺髓样癌（MTC）及甲状腺癌（TC）中的疗效对比数据较为有限。本研究通过分析LIBRETTO-001的患者数据，比较了一线使用塞尔帕替尼（塞尔帕替尼组）与先接受一线标准治疗、后续再使用塞尔帕替尼（对照组）患者的临床结局，包括治疗终止时间（TTD）、至下次治疗或死亡时间（TTNT-D）、疾病进展时间（TTP）及客观缓解率（ORR）。总体而言，一线塞尔帕替尼组在TTD、TTNT-D和TTP方面均优于一线对照组。TTD的风险比（HR）分别为：NSCLC 0.29、MTC 0.15、TC 0.08；TTNT-D的HR分别为：NSCLC 0.48、MTC 0.11、TC 0.09；TTP的HR分别为：NSCLC 0.54、MTC 0.15、TC 0.12。一线塞尔帕替尼组的ORR显著高于一线对照组（NSCLC：85.3% vs. 39.7%；MTC：82.6% vs. 15.2%；TC：81.8% vs. 31.8%）。对于晚期/转移性RET激活肿瘤患者，一线使用塞尔帕替尼相较于一线对照治疗方案能显著改善临床结局。

原文链接：

Comparative Effectiveness of First-Line Selpercatinib versus Standard Therapies in Patients with RET-Activated Cancers: An Exploratory Interpatient Analysis of LIBRETTO-001